Evidence map›Paper›PMID 42397543›Full record

ReviewInfection2026

Double agent: how Escherichia coli switches from commensal to pathogen in the urinary tract infection.

Sabiha Gul

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sabiha GulUniversity of Campania Luigi Vanvitelli ' and AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. Sabiha.gul@unicampania.it.ORCID http://orcid.org/0000-0002-0289-5392

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli exhibits a dual nature as both a beneficial gut commensal and the predominant cause of community-acquired urinary tract infections (UTIs) worldwide. This review synthesizes current evidence establishing phenotypic plasticity the capacity for dynamic, non-heritable, and reversible adaptation as a central determinant of uropathogenic E. coli pathogenesis, distinct from stable genetic resistance. From a multilayered perspective, a comprehensive analysis is provided of how genomic diversity, host-pathogen interactions at the bladder epithelium, and exposure to clinically relevant antibiotics collectively drive morphological and regulatory reprogramming. These adaptations include surface roughening, filamentation, and RpoS-mediated persistence, along with (p)ppGpp stringent response and EnvZ/OmpR two-component system signaling, which enhance bacterial survival independently of genetic resistance mutations. The review further discusses how these mechanisms establish a coordinated survival matrix, creating a fundamental disconnect between standard antibiotic susceptibility testing and the host-associated phenotypes that characterize actual infections. Unlike genetically resistant bacteria that grow at elevated antibiotic concentrations, phenotypically tolerant cells exhibit normal MICs but require prolonged killing times, explaining why recurrent UTIs occur despite appropriate therapy. Finally, recent advances, including phage vB_EcoP_P64441 combined with cefotaxime for biofilm disruption, glucose-mediated gentamicin tolerance targeting metabolic pathways, and HDAC inhibitors such as valproic acid for host-directed epigenetic reprogramming, offer new opportunities to break the debilitating cycle of recurrent UTIs affecting millions worldwide.

Indexed as

Antibiotic toleranceHost-pathogen interactionPhenotypic plasticityUrinary tract infectionUropathogenic Escherichia coli

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.